141 related articles for article (PubMed ID: 36757426)
1. Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway.
Huang S; Wu B; He Y; Qiu R; Yang T; Wang S; Lei Y; Li H; Zheng F
Hepatol Commun; 2023 Mar; 7(3):e0045. PubMed ID: 36757426
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose cotransporter 2 inhibitor canagliflozin alleviates vascular calcification through suppression of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome.
Chen A; Lan Z; Li L; Xie L; Liu X; Yang X; Wang S; Liang Q; Dong Q; Feng L; Li Y; Ye Y; Fu M; Lu L; Yan J
Cardiovasc Res; 2023 Oct; 119(13):2368-2381. PubMed ID: 37523743
[TBL] [Abstract][Full Text] [Related]
3. GAS5 protects against nonalcoholic fatty liver disease via miR-28a-5p/MARCH7/NLRP3 axis-mediated pyroptosis.
Chen T; Meng Y; Zhou Z; Li H; Wan L; Kang A; Guo W; Ren K; Song X; Chen Y; Zhao W
Cell Death Differ; 2023 Jul; 30(7):1829-1848. PubMed ID: 37337032
[TBL] [Abstract][Full Text] [Related]
4. Mangiferin Ameliorates HFD-Induced NAFLD through Regulation of the AMPK and NLRP3 Inflammasome Signal Pathways.
Yong Z; Ruiqi W; Hongji Y; Ning M; Chenzuo J; Yu Z; Zhixuan X; Qiang L; Qibing L; Weiying L; Xiaopo Z
J Immunol Res; 2021; 2021():4084566. PubMed ID: 34734090
[TBL] [Abstract][Full Text] [Related]
5. Caveolin-1 ameliorates acetaminophen-aggravated inflammatory damage and lipid deposition in non-alcoholic fatty liver disease via the ROS/TXNIP/NLRP3 pathway.
Jiang X; Li Y; Fu D; You T; Wu S; Xin J; Wen J; Huang Y; Hu C
Int Immunopharmacol; 2023 Jan; 114():109558. PubMed ID: 36700765
[TBL] [Abstract][Full Text] [Related]
6. The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.
Thrailkill KM; Nyman JS; Bunn RC; Uppuganti S; Thompson KL; Lumpkin CK; Kalaitzoglou E; Fowlkes JL
Bone; 2017 Jan; 94():141-151. PubMed ID: 27989651
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis.
Long Q; Li L; Yang H; Lu Y; Yang H; Zhu Y; Tang Y; Liu C; Yuan J
Int Immunopharmacol; 2022 Sep; 110():109024. PubMed ID: 35841866
[TBL] [Abstract][Full Text] [Related]
8. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns.
Shao M; Chen D; Wang Q; Guo F; Wei F; Zhang W; Gan T; Luo Y; Fan X; Du P; Liu Y; Ma X; Ren G; Song Y; Zhao Y; Qin G
Diabetologia; 2024 Apr; 67(4):738-754. PubMed ID: 38236410
[TBL] [Abstract][Full Text] [Related]
9. Canagliflozin inhibits inflammasome activation in diabetic endothelial cells - Revealing a novel calcium-dependent anti-inflammatory effect of canagliflozin on human diabetic endothelial cells.
Li X; Kerindongo RP; Preckel B; Kalina JO; Hollmann MW; Zuurbier CJ; Weber NC
Biomed Pharmacother; 2023 Mar; 159():114228. PubMed ID: 36623448
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms.
Osataphan S; Macchi C; Singhal G; Chimene-Weiss J; Sales V; Kozuka C; Dreyfuss JM; Pan H; Tangcharoenpaisan Y; Morningstar J; Gerszten R; Patti ME
JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843877
[TBL] [Abstract][Full Text] [Related]
11. Pyrroloquinoline quinone ameliorates diabetic cardiomyopathy by inhibiting the pyroptosis signaling pathway in C57BL/6 mice and AC16 cells.
Qu XF; Zhai BZ; Hu WL; Lou MH; Chen YH; Liu YF; Chen JG; Mei S; You ZQ; Liu Z; Zhang LJ; Zhang YH; Wang Y
Eur J Nutr; 2022 Jun; 61(4):1823-1836. PubMed ID: 34997266
[TBL] [Abstract][Full Text] [Related]
12. Streptozotocin-Treated High Fat Fed Mice: A New Type 2 Diabetes Model Used to Study Canagliflozin-Induced Alterations in Lipids and Lipoproteins.
Yu T; Sungelo MJ; Goldberg IJ; Wang H; Eckel RH
Horm Metab Res; 2017 May; 49(5):400-406. PubMed ID: 28395380
[TBL] [Abstract][Full Text] [Related]
13. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy.
Yu X; Hao M; Liu Y; Ma X; Lin W; Xu Q; Zhou H; Shao N; Kuang H
Eur J Pharmacol; 2019 Dec; 864():172715. PubMed ID: 31593687
[TBL] [Abstract][Full Text] [Related]
14. Salvianolic acid B ameliorates non-alcoholic fatty liver disease by inhibiting hepatic lipid accumulation and NLRP3 inflammasome in ob/ob mice.
Meng LC; Zheng JY; Qiu YH; Zheng L; Zheng JY; Liu YQ; Miao XL; Lu XY
Int Immunopharmacol; 2022 Oct; 111():109099. PubMed ID: 35932615
[TBL] [Abstract][Full Text] [Related]
15. Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells.
Uthman L; Kuschma M; Römer G; Boomsma M; Kessler J; Hermanides J; Hollmann MW; Preckel B; Zuurbier CJ; Weber NC
Cardiovasc Drugs Ther; 2021 Dec; 35(6):1083-1094. PubMed ID: 33048256
[TBL] [Abstract][Full Text] [Related]
16. The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1α signalling pathway.
Yang X; Liu Q; Li Y; Tang Q; Wu T; Chen L; Pu S; Zhao Y; Zhang G; Huang C; Zhang J; Zhang Z; Huang Y; Zou M; Shi X; Jiang W; Wang R; He J
Adipocyte; 2020 Dec; 9(1):484-494. PubMed ID: 32835596
[TBL] [Abstract][Full Text] [Related]
17. Melatonin ameliorates hepatic steatosis by inhibiting NLRP3 inflammasome in db/db mice.
Yu Y; Chen D; Zhao Y; Zhu J; Dong X
Int J Immunopathol Pharmacol; 2021; 35():20587384211036819. PubMed ID: 34399601
[TBL] [Abstract][Full Text] [Related]
18. Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation.
Kabil SL; Mahmoud NM
Eur J Pharmacol; 2018 Jun; 828():135-145. PubMed ID: 29608898
[TBL] [Abstract][Full Text] [Related]
19. Salidroside protects pancreatic β-cells against pyroptosis by regulating the NLRP3/GSDMD pathway in diabetic conditions.
Zhou J; Yan S; Guo X; Gao Y; Chen S; Li X; Zhang Y; Wang Q; Zheng T; Chen L
Int Immunopharmacol; 2023 Jan; 114():109543. PubMed ID: 36508922
[TBL] [Abstract][Full Text] [Related]
20. Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.
Woods TC; Satou R; Miyata K; Katsurada A; Dugas CM; Klingenberg NC; Fonseca VA; Navar LG
Am J Nephrol; 2019; 49(4):331-342. PubMed ID: 30921791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
